Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
3 July 2025
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
1 May 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
30 April 2025
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
30 April 2025
An MSKCC study continues to show a 100% response rate in pre-operative rectal cancer.
30 April 2025
Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
29 April 2025
The CAPItello-280 castrate-resistant prostate cancer trial is discontinued early.
28 April 2025
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.